北京医院生物样本库保存样本的回顾性安全筛查研究  

A retrospective safety study on screening of the samples in the clinical biobank of Beijing Hospital

作　　者：李贺鑫[1] 汤小琨 许思源 罗玄梅 孙高远 许宏涛[3] 张鹏俊[4] 肖飞[1] Li Hexin;Tang Xiaokun;Xu Siyuan;Luo Xuanmei;Sun Gaoyuan;Xu Hongtao;Zhang Pengjun;Xiao Fei(Clinical Biobank,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Beijing Hospital,National Center of Gerontology,the MOH Key Laboratory of Geriatrics,Beijing 100730,China;Department of Clinical Laboratory,National Center of Gerontology,National Health Commission,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Scientific Research Administration,Beijing Hospital,National Center of Gerontology,Beijing 100730,China)

机构地区：[1]北京医院临床生物样本管理中心,国家老年医学中心,中国医学科学院老年医学研究院,100730 [2]北京医院,国家老年医学中心,国家卫生健康委北京老年医学研究所,国家卫生健康委北京老年医学重点实验室,中国医学科学院老年医学研究院,100730 [3]北京医院检验科,国家老年医学中心,中国医学科学院老年医学研究院,100730 [4]北京医院科研处,国家老年医学中心,中国医学科学院老年医学研究院,100730

出　　处：《中华预防医学杂志》2021年第9期1149-1152,共4页Chinese Journal of Preventive Medicine

基　　金：十三五重点研发计划(2018YFC2000505);北京医院课题(BJ-2020-025)。

摘　　要：对北京医院生物样本库在特定时间段保存的样本进行回顾性横断面研究,检测2019新型冠状病毒(SARS-Cov-2),以防止发生实验室污染和次生危害,成为潜在的传染源,同时建立生物样本库回顾性安全筛查体系。选取2019年11月1日至2020年1月22日期间北京医院生物样本库接收的呼吸与危重症科及发热门诊的样本,包括血清(n=79)、尿液(n=20)、粪便(n=42)和肺泡灌洗液(n=21),共162例样本,分别进行SARS-Cov-2核酸检测和血清学抗体检测,以结果的阴阳性界定保存样本安全性。SARS-Cov-2核酸检测和血清学抗体检测结果均显示为阴性,提示该生物样本库所储存样本的安全性较佳。本研究通过建立生物样本库回顾性安全筛查体系,对新型冠状病毒肺炎疫情爆发初期采集保存的高风险样本进行重点排查,以确保生物样本库的安全性。To investigate whether the laboratory specimens preserved in Beijing Hospital Biobank during a specific period had been contaminated by SARS-Cov-2 through a cross-sectional study,and to establish a retrospective biobank safety screening system.Laboratory specimens were collected from the Department of Respiratory and Critical Care Medicine and the Fever Clinic of Beijing Hospital from November 1,2019 to January 22,2020,nucleic acid and serological antibody testing were performed for SARS-CoV-2 in these specimens(including 79 serum,20 urine,42 feces and 21 bronchoalveolar lavage fluid specimens).The safety of the stored samples during this period was defined by negative and positive results.Both the nucleic acid test and serological antibody test showed negative for SARS-CoV-2,indicating that these specimens were safely stored in the biobank.High-risk specimens collected in our hospital during the early stage of the COVID-19 outbreak are free of SARS-CoV-2,and a safety screening strategy for the clinical biobank is established to ensure the biosafety of these samples.

关 键 词：生物样本库 新型冠状病毒 生物危害限制 生物安全 

分 类 号：R197.3[医药卫生—卫生事业管理]